About the study
ASPIRING (Antiplatelet Secondary Prevention International Randomised trial after INtracerebral haemorrhage) is an investigator-led, multicentre, prospective, randomised, open-label, blinded outcome (PROBE), parallel-group clinical trial which aims to determine if antiplatelet monotherapy is of overall net benefit in reducing the incidence of serious vascular events compared to avoiding antiplatelet therapy for adults with a history of spontaneous ICH.
ASPIRING will recruit patients from hospital sites, stroke units, rehabilitation wards, and outpatient clinics in Australia, China, New Zealand and Vietnam, and selected other countries.
Recruitment target (pilot phase): 120 participants
Recruitment target (main phase): 4,148 participants
Total number of participants randomised to date:80
Total number of participants “randomised” from Australia: 7
Total number of participants “randomised” from China: 73